GT Biopharma Inc.

GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform. The company develops NK cell engager-based candidates designed to help natural killer cells recognize and attack cancer cells, supporting research in hematologic malignancies, solid tumors, and autoimmune conditions. Its current pipeline includes programs such as GTB-3650, GTB-5550, and GTB-7550, which reflect the company’s emphasis on targeted biologic therapies that work through immune cell engagement rather than traditional chemotherapy approaches. GT Biopharma’s work is centered on advancing novel cancer and immune-modulating treatments through product development, clinical research, and commercialization efforts in the biotechnology market.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Michael Martin Breen L.L.B.

Employees

1

Headquarters

San Francisco, CA, United States

Website

www.gtbiopharma.com